What is the primary driver behind UnitedHealth Group's revenue growth in Q2 2002?

Revenue growth was primarily driven by an increase in Uniprise's large employer customer base, price increases in excess of 13% on UnitedHealthcare's risk-based commercial products, and growth in specialized care services and healthcare services segments. This growth was achieved despite targeted withdrawals from unprofitable risk-based arrangements and benefit design changes in certain Medicare markets, indicating a strategic shift towards more profitable business.

How has the adoption of SFAS No. 142 impacted the company's financial results?

The adoption of SFAS No. 142, effective January 1, 2002, eliminated the amortization of goodwill and other indefinite-lived intangible assets. This has a favorable impact on reported net earnings and earnings per share. For instance, reported diluted EPS increased 49% year-over-year, while on a comparable basis (assuming SFAS 142 was effective in both periods), the increase was 35%. This accounting change makes the reported earnings appear higher than they would have under previous accounting rules.

What is the company's strategy regarding unprofitable business segments or markets?

UnitedHealth Group is actively withdrawing from unprofitable risk-based arrangements, particularly those with customers using multiple carriers, and making benefit design changes in certain Medicare markets. This strategy aims to improve overall profitability and focus on higher-margin business, as evidenced by the improvement in the medical care ratio and the shift towards fee-based products.

What is the company's outlook on its debt and liquidity?

The company maintains a strong liquidity position with over $5.7 billion in cash and investments as of June 30, 2002. It manages its capital structure to maintain financial flexibility, with a self-imposed debt-to-total-capital ratio limit of 30%. The company has significant credit facilities available and is in compliance with all debt covenants. The strategy focuses on optimizing cost of capital and return on equity while maintaining a prudent level of leverage.

UNH 10-Q Quarterly Report Q2 FY2002 — Revenue, Net Income, EPS

Summary

UnitedHealth Group Inc. (UNH) reported strong financial results for the second quarter and first half of 2002, demonstrating robust growth and improved profitability. Total revenues increased by 5% year-over-year, reaching $6.1 billion for the quarter and $12.1 billion for the first six months. Net earnings saw a significant increase of 33% for the quarter and 29% for the half-year, with diluted earnings per share rising to $1.01 from $0.68 in the prior year's second quarter. The company benefited from a strategic shift towards higher-margin fee-based products and away from unprofitable risk-based arrangements, along with premium yield increases and operating efficiencies. The medical care ratio improved, reflecting better cost management and favorable development of prior period medical cost estimates. Management has also successfully integrated the adoption of SFAS No. 142, which eliminates the amortization of goodwill and other indefinite-lived intangible assets, positively impacting reported earnings.

Key Highlights

1Total revenues grew 5% year-over-year to $6.1 billion in Q2 2002 and $12.1 billion in H1 2002.
2Net earnings increased significantly, up 33% in Q2 and 29% in H1, driven by revenue growth and margin expansion.
3Diluted EPS rose to $1.01 in Q2 2002, a 49% increase from $0.68 in Q2 2001.
4Medical care ratio (excluding AARP) improved to 81.2% from 84.0% in the prior year's quarter, indicating better cost control.
5Operating margin expanded to 8.6% from 6.6% in Q2 2001, reflecting operational efficiencies and strategic business mix changes.
6Cash flow from operations was strong at over $1.0 billion for the first six months of 2002.
7The company adopted SFAS No. 142, resulting in no amortization of goodwill and other indefinite-lived intangible assets, boosting reported earnings.

UNITEDHEALTH GROUP INC Quarterly Report for Q2 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions